Cymabay Therapeu Insiders

CBAYDelisted Stock  USD 11.83  0.27  2.34%   
Cymabay Therapeu employs about 101 people. The company is managed by 13 executives with a total tenure of roughly 24 years, averaging almost 1.0 years of service per executive, having 7.77 employees per reported executive. Break down of Cymabay Therapeu's management performance can provide insight into the company performance.
Daniel Menold  President
Vice President - Finance, Principal Financial Officer, Principal Accounting Officer
  
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Cymabay Therapeu Management Team Effectiveness

The company has return on total asset (ROA) of (0.2205) % which means that it has lost $0.2205 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6417) %, meaning that it created substantial loss on money invested by shareholders. Cymabay Therapeu's management efficiency ratios could be used to measure how well Cymabay Therapeu manages its routine affairs as well as how well it operates its assets and liabilities.

Cymabay Therapeu Workforce Comparison

Cymabay Therapeu is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 3,026. Cymabay Therapeu holds roughly 101 in number of employees claiming about 3% of equities under Health Care industry.

Cymabay Therapeu Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cymabay Therapeu insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cymabay Therapeu's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Cymabay Therapeu insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Cymabay Therapeu Notable Stakeholders

A Cymabay Therapeu stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Cymabay Therapeu often face trade-offs trying to please all of them. Cymabay Therapeu's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Cymabay Therapeu's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Daniel MenoldVice President - Finance, Principal Financial Officer, Principal Accounting OfficerProfile
Sujal ShahCFO and SecretaryProfile
Charles McWherterChief Scientific Officer and Sr. VPProfile
BA BAChief OfficerProfile
Paul QuinlanGeneral Counsel, Corporate SecretaryProfile
Patrick OMaraSenior DevelopmentProfile
Robert MartinSenior DevelopmentProfile
Klara DickinsonEasonChief OfficerProfile
MBA MDChief OfficerProfile
Ken BoehmSenior ResourcesProfile
Harish CFAChief OfficerProfile
Ben KozubHead CommercialProfile
Becki FiliceSenior LeadershipProfile

About Cymabay Therapeu Management Performance

The success or failure of an entity such as Cymabay Therapeu often depends on how effective the management is. Cymabay Therapeu management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Cymabay management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Cymabay management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California. Cymabay Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 59 people.
Please note, the imprecision that can be found in Cymabay Therapeu's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Cymabay Therapeu. Check Cymabay Therapeu's Beneish M Score to see the likelihood of Cymabay Therapeu's management manipulating its earnings.

Cymabay Therapeu Workforce Analysis

Traditionally, organizations such as Cymabay Therapeu use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Cymabay Therapeu within its industry.

Cymabay Therapeu Manpower Efficiency

Return on Cymabay Therapeu Manpower

Revenue Per Employee307.7K
Revenue Per Executive2.4M
Net Loss Per Employee1M
Net Loss Per Executive8.1M
Working Capital Per Employee3.6M
Working Capital Per Executive28.2M
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Other Consideration for investing in Cymabay Stock

If you are still planning to invest in Cymabay Therapeu check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cymabay Therapeu's history and understand the potential risks before investing.
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Fundamental Analysis
View fundamental data based on most recent published financial statements
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets